ClinicalTrials.gg
Active, not recruitingNCT04215146Updated Jan 16, 2025Results posted

A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study

A Phase 2 interventional study of Paclitaxel and Pelareorep in Breast Cancer Metastatic, sponsored by Oncolytics Biotech. Active, not recruiting at 18 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-16.

Sponsored by Oncolytics Biotech · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing avelumab in Breast Neoplasms — none open to participants now, 5 under way, none of them phase 3. avelumab · Breast Neoplasms.

Enrollment
6th of 10
48 · median 72
Started
2020
with 1 other
Phase 2
5 of 10
none open now
Registered
8th of 10
by date
Lead sponsor
1 of 10
Oncolytics Biotech

Among the 10 studies testing avelumab in Breast Neoplasms, this one is the 6th largest by enrollment, is one of 2 that started in 2020, is one of 5 in phase 2, and was the 8th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

None of the 10 studies testing avelumab in Breast Neoplasms is open now. The open studies under Breast Neoplasms, anywhere →

About avelumab

avelumab: first FDA approval 2017 (BAVENCIO), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing avelumab in Breast Neoplasms as a file.
02

Study summary

The purpose of this study is to find out the possible anti-cancer effect of pelareorep in combination with chemotherapy [paclitaxel] and avelumab in treating a type of breast cancer called Hormone Receptor positive (HR+)/Human Epidermal Growth Factor Receptor 2 negative(HER2-) breast cancer, which is either locally advanced or has metastasized (cancer that has spread in your body). The study will investigate if pelareorep in combination with paclitaxel and avelumab is more effective than paclitaxel alone, or pelareorep and paclitaxel. The safety of the combination treatments will also be evaluated.

Read the detailed description

This is an open-label randomized Phase 2, 3-cohort study to evaluate the safety and efficacy of pelareorep, paclitaxel and avelumab in Hormone Receptor+ (HR+)/Human Epidermal Growth Factor Receptor 2 negative (HER2-) with endocrine-refractory metastatic breast cancer.

Patients will be randomized to one of three treatment cohorts: paclitaxel alone, pelareorep + paclitaxel, or pelareorep + paclitaxel + avelumab. A three patient safety run-in will be conducted in the cohort for pelareorep + paclitaxel + avelumab prior to beginning randomization into all three cohorts.

Patients will give mandatory blood samples and optional tumor biopsies, which will be analyzed for biomarkers to determine the immunological changes within the tumor microenvironment and peripheral blood in patients treated with paclitaxel alone, in combination with pelareorep, and in combination with pelareorep and avelumab.

03

Conditions studied

  • Breast Cancer Metastatic

Browse trials for

Keywords

  • Breast
  • Breast Cancer
  • Breast Cancer Metastatic
  • Locally Advanced Breast Cancer
  • Pelareorep
  • Avelumab
  • Paclitaxel
  • Reovirus
  • Oncolytic virus
  • HR+ breast cancer
  • HER2- breast cancer
  • Breast malignancy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Female patients ≥ 18 years of age at the time of signing the form (ICF).
  2. Must have a histological/cytological diagnosis of breast cancer. Disease must be:

    • Positive for estrogen receptor (ER) and/or progesterone receptor (PgR) as defined by

      ≥ 1% tumor cell nuclei immunoreactive.

    • Negative for amplification / overexpression as defined per the American Society of Clinical Oncology - College of American Pathologists (ASCO-CAP) guidelines. However, patients with HER2 equivocal disease for whom HER2 targeted therapy isn't indicated are also eligible for enrollment.
  3. performance status of 0-1
  4. Must have unresectable locally advanced or disease, for which no curative therapy exists and for which systemic chemotherapy is indicated.
  5. as defined by Version 1.1
  6. Prior Hormonal Therapy:

    • Patients must have progressed on at least 1 hormone-based therapy with a CDK4/6 inhibitor. Patients who received a CDK4/6 inhibitor in the setting and progressed while on or within 6 months of discontinuation of CDK4/6 inhibitor therapy are eligible.
    • Prior mTOR inhibitor therapy is allowed but is not required.
  7. Ability to understand and willingness to sign IRB-approved informed consent.
  8. Willing to provide blood samples for research
  9. Adequate organ function as measured by the following criteria, obtained ≤ 2 weeks prior to registration:

    Hematology:

    • Neutrophils ≥ 1.5 x 10\^9/L
    • ≥ 100 x 10\^9/L
    • Lymphocytes ≥ 0.8 x 10\^9/L
    • \< 1.5x (Unless on therapeutic anticoagulation)
    • PTT \< 1.5x ULN

    Biochemistry:

    • Serum Creatinine ≤ 1.5x ULN
    • Total ≤ 1.0x ULN (unless due to Gilbert's Disease and direct bilirubin \<ULN)
    • and AST ≤ 3x ULN (Note: ≤ 5x ULN if documented liver metastasis)
    • Proteinuria ≤ Grade 2* (using spot testing; if Grade 3 repeat with mid-stream urine; if still Grade 3 then urine collection for 24 hours to confirm Grade 0, 1 or 2) *as per National Cancer Institute Common Terminology Criteria for Adverse ()
  10. Women must not be pregnant or breastfeeding since we do not know the effects of the study drugs on the fetus or breastfeeding child. All sexually active females of (not surgically sterilized and between menarche and 1 year post menopause) must have a blood test to rule out pregnancy within 2 weeks prior to registration.
  11. Sexually active women of child-bearing potential with a non-sterilized male partner must agree to use 2 methods of adequate (hormonal plus barrier or 2 barrier forms) OR abstinence prior to study entry, for the duration of study participation, and for 3 months following last dose of study drugs. Method of contraception must be documented. NOTE: If a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately.

Exclusion criteria

Exclusion Criteria:

  1. No major surgery within 21 days prior to beginning study treatment. Major surgery >21 days prior to beginning study treatment is permitted provided that the patient has recovered adequately to receive systemic chemotherapy. NOTE: Placement of a vascular access device is not considered major surgery.
  2. Patients who have received radiation treatment within 14 days of beginning study treatment are excluded. Patients who have received palliative radiation ≥ 14 days prior to beginning study treatment may enroll if they have recovered from all local and systemic side effects to ≤ Grade 1 ().
  3. No prior chemotherapy in the advanced/ setting is allowed. Patients may have received chemotherapy in the (neo) setting. Patients receiving (neo)adjuvant taxanes must have a disease-free interval of at least 12 months.
  4. No known active, uncontrolled or symptomatic Central Nervous System (CNS) metastases, carcinomatous meningitis, or as indicated by clinical symptoms,cerebral edema, and/or progressive growth. Patients with treated with radiation therapy (Whole-Brain Radiation Therapy [WBXRT] or Stereotactic Radiotherapy [SRS]) are eligible if, >28 days following completion of XRT, they show stable disease on post-treatment MRI/CT, are off , and are neurologically stable.
  5. No known history of other , except for adequately treated non-melanoma skin cancer or solid tumors curatively treated with no evidence of disease for >3 years.
  6. Not on chronic therapy including, but not exclusively, steroids (≥ 10 mg prednisone a day or equivalent) or monoclonal antibodies, chronic methotrexate or cyclophosphamide, tacrolimus or sirolimus.
  7. No known infection. Testing not required in absence of clinical suspicion.
  8. No known active Virus (HBV) or Virus (HCV) infection or undergoing anti-viral treatment. Testing for HBV/HCV is not required in absence of clinical suspicion.
  9. No concurrent disease or condition that would interfere with study participation or safety,such as any of the following:

    • Active, infection either Grade >2 by CTCAE V5.0 or requiring the use of parenteral anti-microbial agents within 14 days before registration.
  10. No active or history of any disease (patients with diabetes Type 1, vitiligo, psoriasis, hypo- or hyperthyroid disease not requiring immunosuppressive treatment are eligible) or immunodeficiencies.
  11. Patients may not have evidence of uncontrolled cardiovascular conditions, including uncontrolled hypertension, uncontrolled cardiac arrhythmias, symptomatic congestive heart failure ( [NYHA] Class III or higher), unstable angina, or myocardial infarction within the past 6 months prior to registration. NOTE: Patients with asymptomatic rate-controlled atrial fibrillation may participate.
  12. Patients may not have other significant diseases (for example, inflammatory bowel disease), which, in the opinion of the Investigator, might impair the patient's tolerance of trial treatment.
  13. Patients with a known allergy to any of the study medications, their analogues, or in the various formulations of any agent are not eligible.
  14. Patients who have to treatment with paclitaxel and/or neuropathy >Grade 2 are not eligible.
  15. Patients who have not recovered from clinically significant acute toxicities of previous therapy are not eligible, except treatment-related alopecia or stable sensory neuropathy ≤ Grade 2.
  16. No prior therapy with any anti-cancer therapy within 30 days. Prior immunotherapies are prohibited.
  17. No prior therapy with (e.g., anti-PD-1/PD-L1 antibodies), checkpoint agonist agents (e.g., anti-GITR, anti-OX40 antibodies) and/or another active immunotherapy in breast cancer such as cancer vaccines or oncolytic virsus.
  18. Patients with any serious medical or psychiatric illness that could, in the Investigator's opinion, potentially interfere with the completion of the treatment according to the protocol, are not eligible.
  19. Patients with legal incapacity or limited legal capacity are not eligible.
  20. Patients with known alcohol or drug abuse are not eligible.
  21. Patients may not participate in any other therapeutic clinical trials, including those with other investigational agents not included in this trial, throughout the duration of this study.
  22. Patients may not have any vaccine, including against SARS-COV-2 (COVID-19) \<14 days prior to Cycle 1 Day 1 nor in the first cycle of study treatment. Inactivated vaccines (including against COVID-19 or seasonal influenza) are permitted after the first cycle of study treatment is complete.
Terms in these criteria, in plain language(30)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
48 participants (actual)

Study arms

  • Active comparator
    Cohort 1

    Patients receive paclitaxel alone.

    Drug: Paclitaxel

  • Experimental
    Cohort 2

    Patients receive pelareorep + paclitaxel.

    Drug: Paclitaxel · Biological: Pelareorep

  • Experimental
    Cohort 3

    Patients receive pelareorep + paclitaxel + avelumab.

    Drug: Paclitaxel · Biological: Pelareorep · Drug: Avelumab

Interventions

  • Paclitaxel 80 mg/m\^2 1-hour IV infusion on days 1, 8, and 15 of a 28-day cycle.

  • BiologicalPelareorep

    Pelareorep 4.5 x 10\^10 TCID50 1-hour IV infusion days 1, 2, 8, 9, and 15, 16 of a 28-day cycle.

  • Avelumab 10 mg/kg (not more than 800 mg) 1-hour IV infusion days 3 and 17 of a 28-day cycle.

06

What researchers measure

Primary outcomes

  1. Overall Response Rate

    Overall response rate at week 16 according to RECIST V1.1

    Time frame: at week 16

Other outcomes

  1. The Number of Patients With Adverse Events and Serious Adverse Events

    Graded by the NCI CTCAE v. 5.0.

    Time frame: From first day of study treatment to 30 days after of last day of study treatment; up to 27 months

  2. Changes in the Peripheral and Tumor T Cell Clonality.

    Assessed by T cell receptor (CDR3 variable chain) sequencing in all patients.

    Time frame: Up to 2 years of study treatment

  3. Overall Response Rate

    Overall response rate according to RECIST V1.1

    Time frame: Up to 2 years of study participation

  4. Overall Survival

    Overall Survival assessed at end of study

    Time frame: Up to 2 years of study participation

07

Results

Posted Jan 16, 2025

Participant flow

Participant flow — Overall Study
MilestonePaclitaxelPelareorep + PaclitaxelPelareorep + Paclitaxel + Avelumab
Started151617
Completed151617
Not completed000

Outcome measures

PrimaryOverall Response Rate

Overall response rate at week 16 according to RECIST V1.1

Time frame:
at week 16
Reported as:
Number · percentage of participants
Overall Response Rate
percentage of participantsPelareorepPelareorep + PaclitaxelPelareorep + Paclitaxel + Avelumab
Overall Response Rate20 (7.6 to 39.3)31.3 (16.1 to 50.4)14.3 (3.9 to 33.7)
Other pre-specifiedThe Number of Patients With Adverse Events and Serious Adverse Events

Graded by the NCI CTCAE v. 5.0.

Time frame:
From first day of study treatment to 30 days after of last day of study treatment; up to 27 months
Reported as:
Count of participants · Participants
The Number of Patients With Adverse Events and Serious Adverse Events
ParticipantsPaclitaxelPaclitaxel + PelareorepPaclitaxel + Pelareorep + Avelumab
The Number of Patients With Adverse Events and Serious Adverse Events121617
Other pre-specifiedChanges in the Peripheral and Tumor T Cell Clonality.

Assessed by T cell receptor (CDR3 variable chain) sequencing in all patients.

Time frame:
Up to 2 years of study treatment

Results for this outcome have not been posted.

Other pre-specifiedOverall Response Rate

Overall response rate according to RECIST V1.1

Time frame:
Up to 2 years of study participation

Results for this outcome have not been posted.

Other pre-specifiedOverall Survival

Overall Survival assessed at end of study

Time frame:
Up to 2 years of study participation

Results for this outcome have not been posted.

Adverse events

Collected over 27 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pelareorep1/12 (8.3%)0/12 (0%)12/12 (100%)
Pelareorep + Paclitaxel0/16 (0%)4/16 (25%)16/16 (100%)
Pelareorep + Paclitaxel + Avelumab0/17 (0%)13/17 (76.5%)17/17 (100%)
Most frequent serious events
Most frequent serious events
EventPelareorepPelareorep + PaclitaxelPelareorep + Paclitaxel + Avelumab
Febrile neutropeniaBlood and lymphatic system disorders0/120/163/17
Infusion related reactionInjury, poisoning and procedural complications0/120/163/17
MalaiseGeneral disorders0/122/160/17
PyrexiaGeneral disorders0/122/161/17
FatigueGeneral disorders0/120/162/17
Acute respiratory distress syndromeRespiratory, thoracic and mediastinal disorders0/120/162/17
Pericardial effusionCardiac disorders0/121/160/17
Influenza like illnessGeneral disorders0/120/161/17
PneumoniaInfections and infestations0/120/161/17
PneumonitisRespiratory, thoracic and mediastinal disorders0/120/161/17
Most frequent other events
Showing 10 of 63
Most frequent other events
EventPelareorepPelareorep + PaclitaxelPelareorep + Paclitaxel + Avelumab
PyrexiaGeneral disorders1/129/1613/17
FatigueGeneral disorders5/1212/168/17
Neutrophil count decreasedInvestigations3/125/1611/17
White blood cell count decreasedInvestigations3/123/1611/17
AnaemiaBlood and lymphatic system disorders7/126/1610/17
AlopeciaSkin and subcutaneous tissue disorders7/129/168/17
Aspartate aminotransferase increasedInvestigations4/127/169/17
NauseaGastrointestinal disorders5/127/169/17
Infusion related reactionInjury, poisoning and procedural complications1/123/169/17
DiarrhoeaGastrointestinal disorders2/128/168/17

Baseline characteristics

This is an open-label randomized Phase 2, 3-cohort study for patients with hormone receptor (HR)-positive (HR+)/ Human Epidermal Growth Factor Receptor 2 (HER2)-negative (HER2-), endocrine-refractory metastatic breast cancer.

Age, Categorical
Age, Categorical(Participants)PelareorepPelareorep + PaclitaxelPelareorep + Paclitaxel + AvelumabTotal
<=18 years0000
Between 18 and 65 years10141438
>=65 years52310
Age, Continuous
Age, Continuous(years)PelareorepPelareorep + PaclitaxelPelareorep + Paclitaxel + AvelumabTotal
Mean60.5 (46 to 74)52.8 (38 to 71)55.1 (37 to 70)56.2 (37 to 74)
Sex: Female, Male
Sex: Female, Male(Participants)PelareorepPelareorep + PaclitaxelPelareorep + Paclitaxel + AvelumabTotal
Female15161748
Male0000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PelareorepPelareorep + PaclitaxelPelareorep + Paclitaxel + AvelumabTotal
Hispanic or Latino1315
Not Hispanic or Latino14131340
Unknown or Not Reported0033
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PelareorepPelareorep + PaclitaxelPelareorep + Paclitaxel + AvelumabTotal
American Indian or Alaska Native0000
Asian2103
Native Hawaiian or Other Pacific Islander0000
Black or African American1348
White12121337
More than one race0000
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(participants)PelareorepPelareorep + PaclitaxelPelareorep + Paclitaxel + AvelumabTotal
United States15161748
08

Study locations

18 sites
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2020 to primary completion in Aug 2022, 25 months.

Results were first posted in Jan 2025, 2 years 5 months after primary completion.

Of 232 industry-sponsored phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 53. This study's 25 months is below that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 24, 2019
First posted
Jan 2, 2020
StartActual
Jun 10, 2020
Primary completionActual
Aug 1, 2022
CompletionEst.
Jun 2025
Results first posted
Jan 16, 2025
Last update
Jan 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04215146
Lead sponsor
Oncolytics Biotech
Collaborators
PrECOG, LLC.
Responsible party
Sponsor
First posted
Jan 2, 2020
Start date
Jun 10, 2020
Primary completion
Aug 1, 2022
Completion
Jun 2025 (estimated)
Results posted
Jan 16, 2025
Last update
Jan 16, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pelareorep · Avelumab

Start the discussion